Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Enzon Pharma Inc (ENZN) OTHER OTC

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 19,450
  • Shares Outstanding, K 43,870
  • Annual Sales, $ 17,460 K
  • Annual Income, $ 21,640 K
  • 36-Month Beta 1.06
  • Price/Sales 1.11
  • Price/Book 0.89
  • Price/Earnings ttm 1.52
  • Earnings Per Share ttm 0.33
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.50 on 08/13/15
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3610 +21.05%
on 11/11/16
0.4990 -12.42%
on 11/30/16
+0.0624 (+16.66%)
since 11/04/16
3-Month
0.3450 +26.67%
on 10/17/16
0.4990 -12.42%
on 11/30/16
+0.0620 (+16.53%)
since 09/06/16
52-Week
0.3450 +26.67%
on 10/17/16
1.0000 -56.30%
on 12/07/15
-0.5030 (-53.51%)
since 12/04/15

Most Recent Stories

More News
OTC Markets Group Welcomes Enzon Pharmaceuticals, Inc. to OTCQX

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Enzon Pharmaceuticals, Inc. (OTCQX: ENZN), a pharmaceutical company that receives...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Delaware Law by the Board of Enzon Pharmaceuticals Inc.

Levi & Korsinsky announces it has commenced an investigation of Enzon Pharmaceuticals Inc. (NASDAQ: ENZN) concerning possible breaches of Delaware law by the board of directors of the company. To obtain...

Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant

Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, announced...

Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells

Equity Research Institute has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Peregrine Pharmaceuticals...

Guidance & Quarterly Review on Four Biotech Companies

NEW YORK, NY / ACCESSWIRE / August 14, 2015 / Four biotechnology companies reported earnings last week. These companies include Synta Pharmaceuticals (NASDAQ: SNTA), TransEnterix, Inc., (NYSE-MKT: TRXC),...

Technical Coverage on Biotechnology Equities -- Achillion Pharma, CTI BioPharma, Enzon Pharma, Discovery Laboratories, and Pacific Biosciences of California

Equity Research Institute has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), CTI BioPharma Corporation (NASDAQ: CTIC), Enzon Pharmaceuticals Inc. (NASDAQ:...

Technical Scrutiny on Biotech Stocks -- ARIAD Pharma, Array BioPharma, Enzon Pharma, Ironwood Pharma, and Regulus Therapeutics

Editor Note: For more information about this release, please scroll to bottom.

Health of Health Care Stocks: Complementary Research on Enzon Pharmaceuticals, Durect Corporation, Vertex Pharmaceuticals, Advaxis, and Omnicare

Editor Note: For more information about this release, please scroll to bottom.

Nasdaq stocks posting largest volume increases

NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Most active Nasdaq-traded stocks

NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Support & Resistance

2nd Resistance Point 0.4732
1st Resistance Point 0.4516
Last Price 0.4370
1st Support Level 0.4117
2nd Support Level 0.3934

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.